Viva Biotech Holdings Sustainability Profile
Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in 2008, the company has established itself as a prominent provider of drug discovery services, specialising in structure-based drug design and high-throughput screening. Viva Biotech's unique offerings include its proprietary technology platforms that enhance the efficiency of drug development processes, setting it apart in a competitive market. With a strong focus on innovation, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and a robust portfolio of successful projects. Recognised for its expertise and commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to solidify its position as a trusted partner in the global biotech landscape.
DitchCarbon Score
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viva Biotech Holdings's score of 28 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Viva Biotech Holdings's reported carbon emissions
In 2023, Viva Biotech Holdings reported total carbon emissions of approximately 46,731,280 kg CO2e, with Scope 1 emissions at about 1,466,050 kg CO2e and Scope 2 emissions at approximately 45,285,230 kg CO2e. This marks a slight decrease from 2022, when total emissions were about 46,779,490 kg CO2e, with Scope 1 at approximately 1,404,350 kg CO2e and Scope 2 at around 45,376,870 kg CO2e. Viva Biotech has committed to achieving net-zero emissions by 2045, with specific targets set for both Scope 1 and Scope 2 emissions. The company has announced plans for its first green hydrogen project as part of this long-term strategy. The emissions data is not cascaded from any parent organization, indicating that these figures are independently reported by Viva Biotech Holdings. The company has not disclosed any Scope 3 emissions data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 17,280 | 0,000,000 | 0,000,000 |
| Scope 2 | 551,330 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Viva Biotech Holdings's Industry?
How Carbon Intensive is Viva Biotech Holdings's Location?
Viva Biotech Holdings's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Viva Biotech Holdings has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
